stockportfolio.pro
Stocks / ANRO vs NNNN
ANRO vs NNNN
Alto Neuroscience, Inc. and Anbio Biotechnology side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Alto Neuroscience, Inc. (ANRO) | Anbio Biotechnology (NNNN) | |
|---|---|---|
| Market cap | $0.7B | $0.7B |
| Revenue (latest FY) | $0 | $8.65M |
| Net income (latest FY) | $-63.24M | $6.40M |
| Revenue growth (5y CAGR) | — | -28.4% |
| Net margin | — | 74.1% |
| Return on equity | -41.8% | 21.2% |
| P/E ratio | — | 107.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 4 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ANRO — free Open NNNN — freeFrequently asked questions
Which is bigger, ANRO or NNNN?
Alto Neuroscience, Inc. is larger by market capitalization — $0.7B versus $0.7B.
Which grows faster, ANRO or NNNN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.